Supernus says ADHD drug trounces rivals, but shares slideSupernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, Share XSupernus says ADHD drug trounces rivals, but shares slidehttps://pharmaphorum.com/news/supernus-says-adhd-drug-trounces-rivals-but-shares-slide/
Shareholders approve Takeda’s $59bn takeover of ShireTakeda’s $59 billion acquisition of Shire has been backed by shareholders from both companies, clearing the way for Share XShareholders approve Takeda’s $59bn takeover of Shirehttps://pharmaphorum.com/news/shareholders-approve-takedas-59bn-takeover-of-shire/
UCB, Roche, and IQVIA take lead in UK life sciences investmentPharma giant UCB is to invest around £1 billion in the UK as part of a second life Share XUCB, Roche, and IQVIA take lead in UK life sciences investmenthttps://pharmaphorum.com/news/ucb-roche-and-iqvia-take-lead-in-uk-life-sciences-investment/
FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
GSK enters PARP space with TESARO acquisitionGSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its Share XGSK enters PARP space with TESARO acquisitionhttps://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/
Novartis plans UK headquarters move to LondonNovartis is on the move in the UK, relocating its national headquarters from Frimley in Surrey to London Share XNovartis plans UK headquarters move to Londonhttps://pharmaphorum.com/news/novartis-plans-uk-headquarters-move-to-london/
Healios begins trials of mental health app for schoolchildrenDigital health firm Healios is beginning clinical trials of ThinkNinja, an app designed to help children with mental Share XHealios begins trials of mental health app for schoolchildrenhttps://pharmaphorum.com/news/healios-begins-trials-of-mental-health-app-for-schoolchildren/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitravki (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
